Ryba v. Kijakazi

CourtDistrict Court, N.D. Illinois
DecidedSeptember 20, 2021
Docket1:19-cv-03223
StatusUnknown

This text of Ryba v. Kijakazi (Ryba v. Kijakazi) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ryba v. Kijakazi, (N.D. Ill. 2021).

Opinion

UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION

FRANK R.,

Plaintiff, No. 19 CV 3223 v.

KILOLO KIJAKAZI, Magistrate Judge McShain ACTING COMMISSIONER OF SOCIAL SECURITY,1

Defendant.

MEMORANDUM OPINION AND ORDER

Plaintiff Frank R. brings this action under 42 U.S.C. § 405(g) for judicial review of the Social Security Administration’s (SSA) decision denying his application for benefits. For the following reasons, the Court denies plaintiff’s motion for summary judgment [17],2 grants the Acting Commissioner of Social Security’s (Commissioner) motion for summary judgment [25], and affirms the Commissioner’s decision denying plaintiff’s application for benefits. Procedural Background In August 2016, plaintiff filed a Title II application for a period of disability and disability insurance benefits, alleging an onset date of June 29, 2016. [14-1] 379.

1 In accordance with Fed. R. Civ. P. 25(d), Kilolo Kijakazi, the Acting Commissioner of Social Security, is substituted as the defendant in this case in place of the former Commissioner of Social Security, Andrew Saul.

2 Bracketed numbers refer to entries on the district court docket. Referenced page numbers are taken from the CM/ECF header placed at the top of filings, with the exception of citations to the administrative record [14-1], which refer to the page numbers in the bottom right corner of each page. Plaintiff’s claim was denied initially and on reconsideration. [Id.] 428-48. Plaintiff requested a hearing, which was held by an administrative law judge (ALJ) on March 23, 2018. [Id.] 379. In a decision dated June 28, 2018, the ALJ found that plaintiff

was not disabled. [Id.] 379-89. The Appeals Council denied review on March 24, 2019 [id.] 1-6, making the ALJ’s decision the agency’s final decision. See 20 C.F.R. §§ 404.955, 404.981. Plaintiff timely appealed to this Court [1], and the Court has jurisdiction to review the Commissioner’s decision under 42 U.S.C. § 405(g).3 Factual Background Plaintiff, who is now fifty-five years old, see [14-1] 13, sought disability benefits based on his back problems, an impairment of his left knee, and obesity. Before

applying for benefits, plaintiff worked for the same company for almost thirty years, first as a tank washer and then as a manager of a tank-washing facility. [Id.] 403-04. I. Plaintiff’s Back Problems The medical record establishes that plaintiff has a history of low back pain that began in 1998, when he fell off of a trailer at work, and has progressively worsened. [14-1] 685, 732; see also [id.] 660. Plaintiff has described the pain as centered in his

lower back, more severe on his left side, and worse with activity. [Id.] 685. The pain radiates from his back down both of his legs, and plaintiff has experienced numbness, tingling, and cramping. [Id.] 664, 685. Plaintiff has been diagnosed with lumbar radiculopathy. [14-1] 629. An MRI of plaintiff’s spine taken in April 2017 revealed grade II anteriolisthesis at the L5-S1

3 The parties have consented to the exercise of jurisdiction by a United States Magistrate Judge. [10] level of the lumbar spine, significant multilevel spondylosis that is worse at the L4- L5 and L5-S1 levels, severe bilateral foraminal stenosis at the L5-S1 level, and bilateral foraminal stenosis and central canal stenosis at the L3-L4 and L4-L5 levels.

[14-1] 734. A. Lumbar Steroid Injections and Pain Medication Plaintiff has managed his back pain with lumbar steroid injections and pain medication while avoiding, and occasionally voicing strong opposition to having, lumbar surgery. The administrative record reflects that plaintiff began receiving lumbar injections in late 2015 and continued receiving them through early 2018. According

to a January 2016 treatment note prepared by plaintiff’s pain doctor, Omar Said, plaintiff had undergone a transforaminal epidural steroid injection in December 2015. [14-1] 653. Plaintiff told Dr. Said that “he has had good benefit with that procedure,” and he reported that his pain had “decreased to roughly a 3/10.” [Id.]. In his notes assessing plaintiff’s condition, Dr. Said recorded plaintiff’s statement that “he is vehemently oppose [sic] to lumbar spine surgery.” [Id.].

A treatment note prepared by Dr. Said after plaintiff’s February 2016 appointment stated that his December 2015 injection “continues to be beneficial for him and he rates his pain today as a 2 or 3/10.” [14-1] 651. Plaintiff had another lumbar injection in mid-June 2016, and he reported to Dr. Said at a July 25, 2016 follow-up that he experienced “approximately 50% durable relief” from the injection but “his pain is returning at this time.” [14-1] 646. Plaintiff’s pain was worse with activity, but he managed it by resting and taking medication. [Id.]. Dr. Said’s assessment was that the injections provided “good relief” but the relief was “not long lasting.” [Id.].

Plaintiff received another lumbar epidural steroid injection on January 28, 2017. [14-1] 749. At a visit with Dr. Said the next month, plaintiff “endorse[d] only 25% relief for a few days, but now his pain has returned to baseline,” which plaintiff estimated as a 9/10. [Id.] 767. Plaintiff was taking two or three tablets of Norco to manage his pain around this time, and he reported that it was difficult to walk and perform his activities of daily living. [Id.]. Dr. Said discussed the possibility of surgery, but plaintiff was “strongly opposed to consideration of lumbar spine

surgery.” [Id.]. Plaintiff’s next injection was administered on May 6, 2017. [14-1] 748. At a follow-up appointment with Dr. Said three weeks later, plaintiff reported that the injection provided “25% improvement in pain and functionality” and that his pain was down to a 6/10. [Id.] 761. At the same time, plaintiff described his pain as “severe” and “limiting his functionality.” [Id.]. Plaintiff also reported that he was taking

Percocet, which was “more effective for him than the Norco was for his pain.” [Id.]. In his assessment of plaintiff’s condition, Dr. Said opined that the injections “do help considerably . . . but are temporary.” [Id.]. Said discussed surgery with plaintiff, but plaintiff was “hesitant as he is nervous to have large spine surgery and the recovery process that comes with it.” [Id.]. Dr. Said saw plaintiff again on June 19, 2017 and reported that plaintiff had experienced “excellent durable relief” from his May 2017 injection, that plaintiff’s pain was at a 6.5/10, and that plaintiff’s medications “do provide substantial benefit.”

[14-1] 759. Said also noted that plaintiff was then consulting with three surgeons about spinal surgery, but plaintiff wanted “to defer as long as possible.” [Id.]. At a July 18, 2017 follow-up, plaintiff reported to Dr. Said that his pain “is returning,” “averages a 6.5-7/10 in severity,” and “does affect his ability to perform his ADLs and participate in recreational activities.” [14-1] 757. Dr. Said noted that plaintiff’s medications–Topamax, Percocet, and tizanidine–“provide significant benefit.” [Id.].

Plaintiff’s third lumbar injection of 2017 was administered on August 25. [14- 1] 747. At a follow-up evaluation with Dr. Said on September 21, plaintiff “endorse[d] 50% relief, but only for 1 week following the procedure” and that he “continues to have possibly 10% relief,” with his pain averaging a 6-7/10. [Id.] 755.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Barbara Castile v. Michael Astrue
617 F.3d 923 (Seventh Circuit, 2010)
Arnett v. Astrue
676 F.3d 586 (Seventh Circuit, 2012)
Elder v. Astrue
529 F.3d 408 (Seventh Circuit, 2008)
Cheryl Beardsley v. Carolyn Colvin
758 F.3d 834 (Seventh Circuit, 2014)
Mildred Thomas v. Carolyn Colvin
745 F.3d 802 (Seventh Circuit, 2014)
Kenneth Scrogham v. Carolyn Colvin
765 F.3d 685 (Seventh Circuit, 2014)
Willie Curvin v. Carolyn Colvin
778 F.3d 645 (Seventh Circuit, 2015)
Todd Michalec v. Carolyn Colvin
629 F. App'x 771 (Seventh Circuit, 2015)
Daniel Keys v. Nancy A. Berryhill
679 F. App'x 477 (Seventh Circuit, 2017)
Gotoimoana Summers v. Nancy A. Berryhill
864 F.3d 523 (Seventh Circuit, 2017)
Alejandro Moreno v. Nancy Berryhill
882 F.3d 722 (Seventh Circuit, 2018)
Paul Lambert v. Nancy Berryhill
896 F.3d 768 (Seventh Circuit, 2018)
Biestek v. Berryhill
587 U.S. 97 (Supreme Court, 2019)
Bettie Burmester v. Nancy Berryhill
920 F.3d 507 (Seventh Circuit, 2019)
Chic Zoch v. Andrew Saul
981 F.3d 597 (Seventh Circuit, 2020)
Jennifer Karr v. Andrew Saul
989 F.3d 508 (Seventh Circuit, 2021)
Deborah Morgan v. Andrew Saul
994 F.3d 785 (Seventh Circuit, 2021)

Cite This Page — Counsel Stack

Bluebook (online)
Ryba v. Kijakazi, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ryba-v-kijakazi-ilnd-2021.